Patents Assigned to ALECTOR LLC
-
Publication number: 20240132597Abstract: The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured or humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, in treating and/or delaying progression of a disease or injury in an individual in need thereof.Type: ApplicationFiled: December 7, 2023Publication date: April 25, 2024Applicant: Alector LLCInventors: Robert PAUL, Sam JACKSON, Omer Rizwan SIDDIQUI, Michael F. WARD, Felix Leejia YEH, Julie Y. HUANG, Whedy WANG, Yijie LIAO, Brian C. MANGAL
-
Patent number: 11965023Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: May 9, 2022Date of Patent: April 23, 2024Assignee: Alector LLCInventors: Kate Monroe, Helen Lam, Patricia Culp, Arnon Rosenthal
-
Publication number: 20240101681Abstract: The present disclosure is generally directed to the use of antibodies that specifically bind one or more epitopes within a sortilin protein, e.g., human sortilin or mammalian sortilin, for treating and/or delaying progression of a disease, disorder, or injury in an individual in need thereof.Type: ApplicationFiled: December 1, 2021Publication date: March 28, 2024Applicant: Alector LLCInventors: Arnon ROSENTHAL, Felix Leejia YEH, Michael F. WARD, Robert PAUL, Hua LONG, Yijie LIAO
-
Publication number: 20240082395Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.Type: ApplicationFiled: August 23, 2023Publication date: March 14, 2024Applicant: Alector LLCInventors: Andrew Pincetic, Arnon Rosenthal, Seung-Joo Lee
-
Publication number: 20240067723Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: April 10, 2023Publication date: February 29, 2024Applicant: Alector LLCInventors: Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
-
Patent number: 11897968Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK or human MerTK, and use of such compositions in treating an individual in need thereof.Type: GrantFiled: December 11, 2020Date of Patent: February 13, 2024Assignee: ALECTOR LLCInventors: Seung-Joo Lee, Spencer Liang, Angie Yee, Marina Roell, Arnon Rosenthal
-
Patent number: 11779642Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.Type: GrantFiled: December 8, 2017Date of Patent: October 10, 2023Assignee: Alector LLCInventors: Andrew Pincetic, Arnon Rosenthal, Seung-Joo Lee
-
Publication number: 20230295297Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: February 17, 2023Publication date: September 21, 2023Applicant: Alector LLCInventors: Tina SCHWABE, Fracesca AVOGADRI-CONNORS, Helen LAM, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL
-
Publication number: 20230183341Abstract: The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a TREM2 protein, e.g., human TREM2, for use in treating and/or delaying progression of a disease or injury in an individual in need thereof.Type: ApplicationFiled: April 2, 2021Publication date: June 15, 2023Applicant: Alector LLCInventors: Robert PAUL, Michael F. WARD, Hua LONG, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL, Felix Leejia YEH, Sam JACKSON
-
Patent number: 11667699Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: July 30, 2020Date of Patent: June 6, 2023Assignee: Alector LLCInventors: Jeonghoon Sun, Wei-Hsien Ho, Muhammad A. Alhawagri, Philip Ling Kong, Herve Rhinn, Hua Long, Karpagam Srinivasan, Ananya Mitra, Daniel P. Bermingham, Klaus-Dieter Heger, Santiago Viveros Salazar, Francesca Cignarella, Ilaria Tassi, Tina Schwabe, Angie Grace Yee, Arnon Rosenthal
-
Patent number: 11667710Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: September 10, 2020Date of Patent: June 6, 2023Assignee: Alector LLCInventors: Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
-
Publication number: 20230159637Abstract: The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.Type: ApplicationFiled: February 23, 2021Publication date: May 25, 2023Applicants: Alector LLC, Washington UniversityInventors: Francesca CIGNARELLA, Fabia FILIPELLO, Bryan BOLLMAN, Arnon ROSENTHAL, Tina SCHWABE, Ilaria TASSI, Laura PICCIO
-
Patent number: 11634489Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: March 30, 2020Date of Patent: April 25, 2023Assignee: Alector LLCInventors: Tina Schwabe, Eric Brown, Philip Kong, Ilaria Tassi, Seung-Joo Lee, Arnon Rosenthal, Robert Pejchal, Nels P. Nielson
-
Publication number: 20230121869Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: September 13, 2022Publication date: April 20, 2023Applicant: Alector LLCInventors: Andrew Pincetic, Arnon Rosenthal, Helen Lam, Francesca Avogadri-Connors, Seung-Joo Lee
-
Publication number: 20230107639Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.Type: ApplicationFiled: April 21, 2022Publication date: April 6, 2023Applicant: Alector LLCInventors: Kate MONROE, Tina SCHWABE, Francesca AVOGADRI-CONNORS, Ilaria TASSI, Helen LAM, Arnon ROSENTHAL
-
Publication number: 20230047941Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: June 9, 2022Publication date: February 16, 2023Applicant: Alector LLCInventors: Tina SCHWABE, Michael KURNELLAS, Arnon ROSENTHAL, Robert PEJCHAL, Anthony B. COOPER
-
Publication number: 20230035072Abstract: The present disclosure is generally directed to antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics. The present disclosure is further directed to the methods of treating and/or delaying the progression of a disease or injury in an individual by administering such antibodies.Type: ApplicationFiled: December 11, 2020Publication date: February 2, 2023Applicant: Alector LLCInventors: Robert PAUL, Michael F. WARD, Hua LONG, Shiao-Ping LU, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL
-
Publication number: 20230024528Abstract: The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.Type: ApplicationFiled: December 4, 2020Publication date: January 26, 2023Applicant: Alector LLCInventors: Tina SCHWABE, Ilaria TASSI, Arnon ROSENTHAL, Hua LONG, Santiago Viveros SALAZAR
-
Publication number: 20220411503Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: June 2, 2022Publication date: December 29, 2022Applicant: Alector LLCInventors: Kate MONROE, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Francesca AVOGADRI-CONNORS, William MONTEITH
-
Publication number: 20220348656Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: June 9, 2022Publication date: November 3, 2022Applicant: Alector LLCInventors: Tina SCHWABE, Michael KURNELLAS, Arnon ROSENTHAL, Robert PEJCHAL, Anthony B. COOPER
